葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002737 葵花药业

已收盘 04-30 15:00:00

{"stockData":{"symbol":"002737","market":"SZ","secType":"STK","nameCN":"葵花药业","latestPrice":26.52,"timestamp":1714460586000,"preClose":25.92,"halted":0,"volume":12737551,"delay":0,"floatShares":584000000,"shares":584000000,"eps":1.6579,"marketStatus":"已收盘","marketStatusCode":5,"change":0.6,"latestTime":"04-30 15:00:00","open":25.81,"high":27,"low":25.72,"amount":339000000,"amplitude":0.0494,"askPrice":26.52,"askSize":42,"bidPrice":26.51,"bidSize":47,"shortable":0,"etf":0,"ttmEps":1.6579,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":25.92,"symbolType":"stock","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":28.51,"lowLimit":23.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":584000000,"pbRate":3.01,"roa":"--","roe":"5.22%","epsLYR":1.92,"committee":-0.216867,"marketValue":15488000000,"floatMarketCap":15488000000,"peRate":15.99614,"changeRate":0.0231,"turnoverRate":0.0218,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-06。"},"requestUrl":"/m/hq/s/002737/wiki","defaultTab":"wiki","newsList":[{"id":"2431033801","title":"葵花药业（002737）4月29日主力资金净卖出3081.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431033801","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431033801?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:22","pubTimestamp":1714440156,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月29日收盘，葵花药业报收于25.92元，下跌0.54%，换手率2.49%，成交量14.55万手，成交额3.75亿元。近5日资金流向一览见下表：葵花药业融资融券信息显示，融资方面，当日融资买入2513.52万元，融资偿还2142.37万元，融资净买入371.14万元。葵花药业主营业务：各类中成药、化学药品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000018480.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431046060","title":"葵花药业（002737）4月26日主力资金净卖出4646.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431046060","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431046060?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:19","pubTimestamp":1714353582,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月26日收盘，葵花药业报收于26.06元，下跌5.24%，换手率5.3%，成交量30.95万手，成交额7.97亿元。近5日资金流向一览见下表：葵花药业融资融券信息显示，融资方面，当日融资买入4237.64万元，融资偿还6239.66万元，融资净偿还2002.02万元。葵花药业主营业务：各类中成药、化学药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900002376.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430083847","title":"【调研快报】葵花药业接待国盛证券等多家机构调研","url":"https://stock-news.laohu8.com/highlight/detail?id=2430083847","media":"东方财富","top":-1,"share":"https://www.laohu8.com/m/news/2430083847?lang=zh_cn&edition=full","pubTime":"2024-04-28 13:18","pubTimestamp":1714281480,"startTime":"0","endTime":"0","summary":"葵花药业4月28日发布消息，4月26日，公司接待国盛证券等多家机构调研，接待人员副总经理 海洋，财务负责人 吴春红，董事会秘书 周广阔，证券事务代表 李海美，通过电话会议进行。调研主要内容一、公司2023年年度经营情况简介 感谢各位投资者对葵花的关注!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-28/doc-inatkenz4111275.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-04-28/doc-inatkenz4111275.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430779190","title":"葵花药业获信达证券增持评级，2023年业绩创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2430779190","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430779190?lang=zh_cn&edition=full","pubTime":"2024-04-27 15:47","pubTimestamp":1714204062,"startTime":"0","endTime":"0","summary":"4月27日， 葵花药业 获 信达证券 增持评级，近一个月葵花药业获得1份研报关注。研报预计2024-2026年营业收入为63.4亿元、71.31亿元、80.26亿元，同比增速为11%、13%、13%，实现归母净利润分别为12.07亿元、13.34亿元、14.75亿元，同比增长8%、11%、11%。研报认为葵花药业以优异的业绩完成“五五”规划，并提出“六五”规划以实现更高的销售规模目标，击破百亿大关，并力争成为国内家庭常用药领域最具影响力的企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404271558288b59f6b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404271558288b59f6b5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430794898","title":"信达证券给予葵花药业增持评级 2023年业绩创新高 “六五”规划剑指百亿销售规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2430794898","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430794898?lang=zh_cn&edition=full","pubTime":"2024-04-27 15:35","pubTimestamp":1714203305,"startTime":"0","endTime":"0","summary":"信达证券04月27日发布研报称，给予葵花药业（002737.SZ，最新价：26.06元）增持评级。评级理由主要包括：1）以优秀业绩完成“五五”规划，2023年拟分红比例约78%；2）“买、改、联、研、代”策略打造公司第二成长驱动力；3）2023Q1高基数致使2024Q1业绩承压，“六五”规划启动新征程。风险提示：出生人口持续下行风险，市场竞争加剧，销售不达预期，新品推出不及预期风险，产品研发不及预期。文章来源：每日经济新闻原标题：信达证券给予葵花药业增持评级，2023年业绩创新高，“六五”规划剑指百亿销售规模","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404271618008b5a04ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404271618008b5a04ac&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430779640","title":"信达证券：给予葵花药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430779640","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430779640?lang=zh_cn&edition=full","pubTime":"2024-04-27 15:32","pubTimestamp":1714203158,"startTime":"0","endTime":"0","summary":"信达证券股份有限公司唐爱金,章钟涛近期对葵花药业进行研究并发布了研究报告《2023年业绩创新高，“六五”规划剑指百亿销售规模》，本报告对葵花药业给出增持评级，当前股价为26.06元。此外，化药9个产品和中药3个产品完成中试批生产，1个化药产品和1个中药产品验证批生产，1个化药产品完成BE试验。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，增持评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404271534458b59e747&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404271534458b59e747&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430261694","title":"葵花药业连续三年业绩实现两位数增长 苦修内功剑指百亿营收目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2430261694","media":"新浪证券","top":-1,"share":"https://www.laohu8.com/m/news/2430261694?lang=zh_cn&edition=full","pubTime":"2024-04-26 07:59","pubTimestamp":1714089540,"startTime":"0","endTime":"0","summary":"　　4月25日晚间，葵花药业披露2023年年度报告。报告显示，公司报告期内实现营业收入57.00亿元，同比增长11.89%；实现归母净利润11.19亿元，同比增长29.05%；实现扣非净利润10.03亿元，同比增长24.77%。结合往年业绩来看，葵花药业近年业绩表现持续向好，已连续三年实现营收及净利润的同比两位数增长。　　除了营收及净利润保持强劲增长之外，葵花药业的营运能力也呈现出持续增强的态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/observe/2024-04-26/doc-inatcfte5421616.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-04-26/doc-inatcfte5421616.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430523774","title":"图解葵花药业一季报：第一季度单季净利润同比减37.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430523774","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430523774?lang=zh_cn&edition=full","pubTime":"2024-04-26 01:57","pubTimestamp":1714067855,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业2024年一季报显示，公司主营收入15.18亿元，同比下降14.01%；归母净利润2.55亿元，同比下降37.17%；扣非净利润2.37亿元，同比下降39.18%；负债率26.15%，投资收益540.76万元，财务费用-1111.32万元，毛利率56.77%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600002689.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430470927","title":"葵花药业(002737.SZ)发布一季度业绩，净利润2.55亿元，下降37.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430470927","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430470927?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:39","pubTimestamp":1714041550,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布2024年一季度报告，报告期内实现营业收入15.18亿元，同比下降14.01%。归属于上市公司股东的净利润2.55亿元，同比下降37.17%。归属于上市公司股东的扣除非经常性损益的净利润2.37亿元，同比下降39.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110190.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430470532","title":"葵花药业(002737.SZ)发布2023年度业绩，净利润11.19亿元，增长29.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430470532","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430470532?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:37","pubTimestamp":1714041427,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布2023年年度报告，报告期内，公司实现营业收入57亿元，同比增长11.89%。实现归属于上市公司股东的净利润11.19亿元，同比增长29.05%。实现归属于上市公司股东的扣除非经常性损益的净利润10.03亿元，同比增长24.77%。基本每股收益为1.92元。拟向全体股东每10股派发现金红利15元(含税)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110181.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430140640","title":"葵花药业：2023年归母净利润11.19亿元 同比增29.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430140640","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2430140640?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:35","pubTimestamp":1714041300,"startTime":"0","endTime":"0","summary":"格隆汇4月25日｜葵花药业发布2023年报显示，2023年营业收入57.00亿元，比上年同期增加11.89%；归属于上市公司股东的净利润11.19亿元，比上年同期增加29.05%；公司拟向全体股东每10股派发现金红利15.00元(含税)。葵花药业表示，报告期内公司以“小葵花”、“葵花”双品牌驱动，坚定儿药第一核心战略，同时打造黄金单品集群，培育优质潜力品种，引入重点新品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-25/doc-inaszxxu5924565.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-25/doc-inaszxxu5924565.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429027161","title":"葵花药业：公司将在定期报告中披露截至期末的股东人数情况，请参阅相关公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2429027161","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429027161?lang=zh_cn&edition=full","pubTime":"2024-04-23 18:04","pubTimestamp":1713866696,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)04月23日在投资者关系平台上答复投资者关心的问题。投资者：董秘您好！我目前持有贵公司股票，请问公司最新的股东人数是多少？感谢回复。葵花药业董秘：公司将在定期报告中披露截至期末的股东人数情况，请参阅相关公告，感谢关注！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300035540.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2014-12-30","address":"黑龙江省哈尔滨市道里区高新技术产业开发区迎宾路集中区东湖路18号","stockEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0328},{"period":"3month","weight":0.1657},{"period":"6month","weight":0.1185},{"period":"1year","weight":0.0464},{"period":"ytd","weight":0.0208}],"companyName":"葵花药业集团股份有限公司","boardCode":"AI0027","perCapita":"18049股","boardName":"医药制造业","registeredCapital":"58400万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":"　　葵花药业集团股份有限公司主营业务以生产中成药为主导,以“化学药、生物药”和“健康养生品”为两翼,是集药品研发、制造与营销为一体的大型品牌医药集团企业。公司主要产品涵盖呼吸感冒系统用药、消化系统用药、风湿骨病用药、心脑血管用药、妇科用药、补益用药及健康产品。葵花药业获评“2022中国医药社会责任媒体观察公益柱石”;葵花药业获评“2022年度中国医药工业百强系列榜单-中国中药企业TOP100排行榜”第14位。","serverTime":1714735616766,"listedPrice":36.53,"stockholders":"32355人(较上一季度减少7.62%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葵花药业,002737,葵花药业股票,葵花药业股票老虎,葵花药业股票老虎国际,葵花药业行情,葵花药业股票行情,葵花药业股价,葵花药业股市,葵花药业股票价格,葵花药业股票交易,葵花药业股票购买,葵花药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}